US2022054457A2PendingUtilityA2
Methods for treating ocular demodex using spinosad formulations
Assignee: TARSUS PHARMACEUTICALS INCPriority: Dec 15, 2017Filed: Nov 16, 2020Published: Feb 24, 2022
Est. expiryDec 15, 2037(~11.4 yrs left)· nominal 20-yr term from priority
A61P 17/00A61K 31/155A61P 27/02A61P 33/14A61K 47/26A61K 9/0048A61K 9/08A61K 31/422A61K 31/42
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 - 20 . (canceled)
21 . A method for treating an ocular Demodex mite infestation, comprising: topically administering to one or more of the eye, eyelid, or eyelashes of a human patient in need of treatment thereof an effective amount of a composition comprising spinosad.
22 . The method of claim 21 , wherein the composition comprises an eye drop.
23 . The method of claim 21 , wherein the composition comprises an ointment.
24 . The method of claim 21 , wherein the composition comprises a cream.
25 . The method of claim 21 , wherein the composition comprises an emulsion.
26 . The method of claim 21 , wherein the composition comprises a suspension.
27 . The method of claim 21 , wherein the Demodex mite comprises one or more of Demodex folliculorum and Demodex brevis.
28 . The method of claim 21 , wherein the composition further comprises an isoxazoline parasiticide.
29 . The method of claim 28 , wherein the isoxazoline parasiticide comprises lotilaner.
30 . The method of claim 21 , wherein the composition further comprises tea tree oil.
31 . The method of claim 21 , wherein the ocular Demodex mite infestation comprises blepharitis.
32 . The method of claim 21 , wherein the ocular Demodex mite infestation comprises meibomian gland dysfunction.
33 . The method of claim 21 , wherein the ocular Demodex mite infestation comprises ocular rosacea.
34 . The method of claim 21 , wherein the composition further comprises an antibiotic agent.
35 . The method of claim 21 , further comprising confirming the presence of Demodex mites prior to the topically administering.
36 . The method of claim 21 , wherein confirming the presence of Demodex mites comprises identifying cylindrical dandruff, identifying Demodex mites, or testing for the presence of a biomarker associated with Demodex mites.
37 . The method of claim 21 , wherein the composition comprises an additional agent having miticidal activity against the Demodex mite.
38 . The method of claim 21 , wherein the additional agent is selected from the group consisting of: ivermectin, moxidectin, metronidazole, and amitraz.
39 . A method for treating an ocular Demodex mite infestation, comprising: topically administering to one or more of the eyelid or eyelashes of a human patient in need of treatment thereof an effective amount of a composition comprising spinosad.
40 . A method for treating Demodex blepharitis, comprising: topically administering to one or more of the eyelid or eyelashes of a human patient in need of treatment thereof an effective amount of a composition comprising spinosad.Join the waitlist — get patent alerts
Track US2022054457A2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.